Evidence map›Paper›PMID 40681200›Full record

ArticleBMJ open2025

Efficacy and safety of intensive triglyceride-lowering therapy on reducing recurrence of hypertriglyceridemia-associated pancreatitis (REDUCE): protocol for a multicentre, randomised controlled trial.

Xin Xu, Ling Ding, Tao Chen, Gaifang Liu, Lihui Deng, Jinyi Sheng, Chunping Zhu, Jianwen Sheng, Hongwei Zhang, Dong Wu and 8 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07617155 (Effects of GLP-1 Agonists on Prevention of HTG-Induced Acute Pancreatitis Recurrence), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07617155 phase4not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Effects of GLP-1 Agonists on Prevention of HTG-Induced Acute Pancreatitis Recurrence: Protocol for a Randomized Clinical Trial

TypeinterventionalSponsorPeking Union Medical College HospitalRan2026 to 2028Enrolled396ConditionsHypertriglyceridemia Induced Acute Pancreatitis, Recurrent Acute Pancreatitis, Pancreatitis Relapsing, HypertriglyceridemiaArmsSemaglutide, Placebo (Normal Saline)
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Xin Xu *Department of Gastroenterology, Jiangxi Provincial Key Laboratory of Digestive Diseases, Jiangxi Clinical Research Centre for Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Ling Ding *Department of Gastroenterology, Jiangxi Provincial Key Laboratory of Digestive Diseases, Jiangxi Clinical Research Centre for Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Tao ChenDepartment of Clinical Sciences, Tropical Clinical Trials Unit, Liverpool School of Tropical Medicine, Liverpool, UK.
Gaifang LiuDepartment of Gastroenterology, Hebei General Hospital, Shijiazhuang, China.
Lihui DengDepartment of Integrated Traditional Chinese and Western Medicine, West China Centre of Excellence for Pancreatitis, Institute of Integrated Traditional Chinese and Western Medicine, West China-Liverpool Biomedical Research Centre, West China Hospital, Sichuan University, Chengdu, China.ORCID http://orcid.org/0000-0003-1729-9662
Jinyi ShengDepartment of Gastroenterology, Jingdezhen First People's Hospital, Jingdezhen, China.
Chunping ZhuDepartment of Gastroenterology, Ganzhou People's Hospital, Ganzhou, China.
Jianwen ShengDepartment of Gastroenterology, Yichun people's hospital, Yichun, China.
Hongwei ZhangDepartment of Critical Care Medicine, JinJiang Hospital of Traditional Chinese Medicine, Jinjiang, China.
Dong WuDepartment of Gastroenterology, Peking Union Medical College Hospital, Beijing, China.
Wenhua HeDepartment of Gastroenterology, Jiangxi Provincial Key Laboratory of Digestive Diseases, Jiangxi Clinical Research Centre for Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Liang XiaDepartment of Gastroenterology, Jiangxi Provincial Key Laboratory of Digestive Diseases, Jiangxi Clinical Research Centre for Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Lingyu LuoDepartment of Gastroenterology, Jiangxi Provincial Key Laboratory of Digestive Diseases, Jiangxi Clinical Research Centre for Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Huifang XiongDepartment of Gastroenterology, Jiangxi Provincial Key Laboratory of Digestive Diseases, Jiangxi Clinical Research Centre for Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Nong-Hua LuDepartment of Gastroenterology, Jiangxi Provincial Key Laboratory of Digestive Diseases, Jiangxi Clinical Research Centre for Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Lu KeDepartment of Critical Care Medicine, Center of Severe Acute Pancreatitis (CSAP), Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China ndyfy01977@ncu.edu.cn ctgkelu@nju.edu.cn.
Yin ZhuDepartment of Gastroenterology, Jiangxi Provincial Key Laboratory of Digestive Diseases, Jiangxi Clinical Research Centre for Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China ndyfy01977@ncu.edu.cn ctgkelu@nju.edu.cn.ORCID http://orcid.org/0000-0002-7561-2306
Chinese Acute Pancreatitis Clinical Trials Group (CAPCTG)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRecurrence of hypertriglyceridaemia-associated acute pancreatitis (HTG-AP) is common. Uncontrolled HTG after hospital discharge is an important risk factor for recurrence. However, the optimal triglyceride (TG) goal of lipid-lowering therapy for outpatients remains unclear. The efficacy and safety of intensive TG-lowering therapy on reducing recurrence of HTG-AP trial aims to determine whether intensive TG-lowering therapy (with a TG goal of <150 mg/dL (equal to 1.7 mmol/L)), compared with usual care (with a TG goal of <500 mg/dL (equal to 5.65 mmol/L)), can reduce recurrence in patients after a first episode of HTG-AP. METHODS AND ANALYSIS: This is an investigator-initiated, multicentre, open-label, parallel, superiority, randomised, controlled trial. Adult patients who have been successfully treated and discharged from their index episode of HTG-AP will be screened for eligibility after a 4-week to 3-month run-in period in the outpatient setting, and then patients with the fasting serum TG levels ≥150 mg/dL at baseline are eligible. During the study period, a total of 256 study participants will be randomised to receive either intensive TG-lowering therapy or usual care. In the intensive TG-lowering therapy group, the goal of TG levels is lower than 150 mg/dL, which will be monitored at 1 month, 3 months, 6 months, 12 months and 18 months after randomisation. In the usual care group, the goal of TG levels is lower than 500 mg/dL according to the current guidelines. Lifestyle suggestions and TG-lowering agents are the main strategies to manage the lipid level. The primary endpoint is the incidence of recurrent episodes of HTG-AP at 18 months after randomisation. ETHICS AND DISSEMINATION: This study has been approved by the Ethics Committee of the First Affiliated Hospital of Nanchang University (No. 2023101-3). Ethics approval of each participating centre is required before initiation of enrolment. The results of this study will be published in peer-reviewed journals and reported at international conferences. TRIAL REGISTRATION NUMBER: ChiCTR2300073483 (Chinese Clinical Trial Registry) PROTOCOL VERSION: V.4.0 (2024).

Indexed as

HypertriglyceridemiaHypolipidemic AgentsPancreatitisTriglyceridesAdultEquivalence Trials as TopicFemaleHumansMaleMiddle AgedMulticenter Studies as TopicRandomized Controlled Trials as TopicRecurrenceSecondary PreventionTreatment OutcomeHypolipidemic AgentsTriglyceridesLipid disordersPancreatic diseaseRandomized Controlled Trial

Identifiers

PMID40681200
PMCPMC12273170

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.